Citigroup Downgrades Evolent Health to Neutral, Raises Price Target to $6.75
Benzinga Newsdesk 3 months ago
NewsDowngradesAnalyst RatingsPrice Target
Citigroup analyst Daniel Grosslight downgrades Evolent Health (NYSE:EVH) from Buy to Neutral and raises the price target from $5.5 to $6.75.
Citigroup analyst Daniel Grosslight downgrades Evolent Health (NYSE:EVH) from Buy to Neutral and raises the price target from $5.5 to $6.75.